Close Menu

NEW YORK (GenomeWeb) – DermTech announced today that its licensee, DermTech Canada, has received approval to market the company's pigmented lesions assay (PLA) and noninvasive biopsy kit for melanoma detection in Canada.

As part of the approval, DermTech will market and sell the PLA in Canada, while it will process samples at the company's central laboratory in La Jolla, California. The San Diego-based company said that coverage approvals are in process in Canada with an initial focus on British Columbia and Ontario.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
16
Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.